Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: Results of a two-year study

Clinical Drug Investigation

Volumn 23, Issue 7, 2003, Pages 439-450

  Miravitlles, Marc ^a   Zalacain, Rafael ^b   Murio, Cristina ^c   Ferrer, Montserrat ^d   Alvarez Sala, José Luis ^e   Masa, Juan Fernando ^f   Verea, Héctor ^g   Ros, Fernando ^h   Vidal, Rafael ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL GENERAL DE CATALUNYA   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

^h QF Bayer   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CEFUROXIME AXETIL; CLARITHROMYCIN; CLAVULANIC ACID; CORTICOSTEROID; IPRATROPIUM BROMIDE; MOXIFLOXACIN; MUCOLYTIC AGENT; THEOPHYLLINE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONVALESCENCE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0041669566     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323070-00003     Document Type: Article

References (45)

1. Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbations of chronic bronchitis: results from a German population study. Respir Med 2002; 96: 39-51
2. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22
3. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-55
4. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-64
5. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
6. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957-60
7. Sobradillo Peña V, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC Multicentre Epidemiological Study. Chest 2000; 118: 981-9
8. Miravitlles M, Mayordomo C, Artés M, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999; 93: 173-9
9. Oteo J, Alós JI, Gómez-Garcés JL. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. J Antimicrob Chemother 2001; 47: 215-8
10. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-9
11. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antibiotic Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: 81-93
12. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341: 1546-8
13. Blondeau J, Zhao X, Hansen G, et al. Mutant prevention concentrations (MPC) of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-8
14. Jones ME, Karlowsky JA, Blosser-Middleton R, et al. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19: 119-23
15. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002; 46: 522-4
16. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory" quinolones. J Antimicrob Chemother 1999; 43 Suppl. B: 1-11
17. Ackermann G, Schaumann R, Pless B, et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32
18. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-8
19. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 811-8
20. Kreis SR, Herrera N, Golzar N, et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Management 2000; 7: 33-7
21. Miravitlles M, Ros F, Cobos A, et al. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int J Clin Pract 2001; 55: 437-41
22. Landen H, Möller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29: 51-60
23. Lorenz J, Busch W, Thate-Waschke I-M, et al. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61-73
24. Lorenz J, Thate-Waschke I-M, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74-86
25. DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med 2000; 94: 1029-37
26. Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001; 14: 52-9
27. Miravitlles M, Alvarez-Sala JL, Lamarca R, et al. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res 2002; 11: 329-38
28. American Thoracic Society. Statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 Suppl. 5: 77-120
29. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies (statement). Am Rev Respir Dis 1991; 144: 1201-18
30. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6
31. Ferrer M, Alonso J, Morera J. et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072-9
32. Álvarez-Sala JL, Cimas E, Masa JF, et al. Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001; 37: 269-78
33. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814-9
34. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-71
35. Grossman RF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbation of COPD. Chest 1998; 113 (4 Suppl.): 249-55
36. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-52
37. Miravitlles M, Murio C, Guerrero T, et al. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis: a prospective multicenter study in the community. Eur Respir J 2001; 17: 928-33
38. Miravitlles M, Guerrero T, Mayordomo C. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67: 495-501
39. Miravitlles M, Espinosa C, Fernández-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-6
40. Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113: 131-41
41. Wilson R, Schentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24: 639-52
42. Schmidt H, Dalhoff A, Stuertz K, et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998; 42: 1397-407
43. Shalit I, Kletter Y, Halperin D, et al. Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia. Eur J Haematol 2001; 66: 287-96
44. Spiteri M, Rotondetto S, Thomson C, et al. Enhancement of human ciliary function by moxifloxacin, a new 8-methoxyfluoroquinolone. In: Gillespie SH, Tillotson GS, editors. Novel perspectives in antibacterial action. London: Royal Society of Medicine Press Limited, 2002: 35-42
45. Iannini PB, R Kubin, C Reiter. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin [abstract]. Poster presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Annual Meeting, 27-30 September 2002, San Diego, USA, ASM Abstract Book